Professor Simon said:
It is truly an honour to work with this wonderful group of colleagues and to help with this extremely important effort led by Cure Parkinson’s. I look forward to working with Dr Camille Carroll and the rest of the iLCT committee on the difficult task of identifying among many candidates those agents that show the greatest promise for slowing progression of Parkinson’s.”Professor Simon Stott, Cure Parkinson’s
Professor Carroll added:
I am delighted to co-chair the iLCT committee with David. The drive and ambition of Cure Parkinson’s, supported by Van Andel Institute, has transformed the landscape of neuroprotective clinical trial delivery in Parkinson’s. It is a privilege to work with such an incredible team to continue this important initiative.”Professor Camille Carroll, University of Plymouth
Now in its 10th year, the iLCT Committee has evaluated more than 250 drug dossiers and prioritised over 45 drugs to move forward to clinical testing. Currently more than 3,000 people with Parkinson’s have been involved in the 14 completed and 15 ongoing trials of iLCT evaluated compounds. A recent report published by Journal of Parkinson’s Disease showed that nearly 40% of all disease-modifying clinical trials currently taking place have been previously assessed by the International Linked Clinical Trials initiative.
We are sorry that this content was not useful for you
Let us improve this content
Can you tell us how we can improve this content?